Press Release
CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China
SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, “MG-K10” or the “Product”), a Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection, for which the Group holds co-development rights (excluding the indication of atopic dermatitis (AD)) and exclusive commercialization rights, was accepted by the National Medical Products Administration of China (NMPA) on 23 April 2026. The Product is proposed for the treatment of adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms remain inadequately controlled after treatment with intranasal corticosteroids.
The acceptance of the NDA represents an important milestone for the Group’s ophthalmology business, CMS Vision, as it expands its therapeutic focus from ophthalmology into the field of otolaryngology (ENT). It also marks another significant milestone in the Group’s research and development progress in the field of type 2 inflammatory diseases. If the Product is successfully approved for marketing, the Group will leverage its strong academic promotion capabilities and extensive commercialization network to accelerate the commercialization of the Product. It is also expected to further enhance the academic brand influence of CMS Vision in the relevant specialty areas and provide new momentum for the Group’s business growth.
BIC Potential: Dosing once every 4 weeks; Phase III study met the primary endpoint with a favorable safety profile
MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling pathways of the key type 2 inflammatory cytokines IL-4 and IL-13, thereby exerting immunomodulatory effects. It is being developed for the treatment of type 2 inflammatory diseases, including seasonal allergic rhinitis, asthma, atopic dermatitis (AD), prurigo nodularis, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Currently marketed anti-IL-4Rα therapies require administration once every two weeks. MG-K10, with its longer half-life, enabling a once-every-four-weeks dosing regimen. It therefore has the potential to become the first long-acting anti-IL-4Rα monoclonal antibody to be marketed globally, with the potential to be best-in-class. MG-K10 has met the primary endpoint in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial in adult patients with moderate-to-severe seasonal allergic rhinitis. The results of the Phase III study demonstrated that the primary endpoint achieved statistical significance, with significantly superior efficacy compared with the placebo group, and a favorable safety profile.
Focusing on Unmet Needs: ~250 million patients; 62% of moderate-to-severe patients remain inadequately controlled; long-acting breakthrough brings new treatment opportunities
Allergic rhinitis is a chronic inflammatory disease of the nasal mucosa mediated by IgE, with type 2 inflammation as the core pathogenic mechanism. It occurs in susceptible individuals upon exposure to environmental allergens such as pollen and dust mites. In recent years, the prevalence of the disease in China has increased from 11.1% to 17.6%, affecting approximately 250 million people[1], among whom 52.2% are patients with persistent moderate-to-severe disease[2]. The disease burden is significant and has become an important public health issue. Current standard treatments, including intranasal corticosteroids and antihistamines, have notable limitations. 62% of patients with moderate-to-severe disease remain inadequately controlled[3]. Long-term use of intranasal corticosteroids may lead to adverse reactions such as epistaxis[4], while antihistamines are often associated with side effects such as drowsiness[5], indicating significant unmet clinical needs. As a biologic therapy targeting IL-4Rα, MG-K10 can block the type 2 inflammatory pathway at its source. Compared with currently approved biologics targeting the same pathway (which require dosing once every two weeks), MG-K10 achieves a differentiated breakthrough in dosing frequency with its long-acting property allowing administration once every four weeks, thereby significantly extending dosing intervals. This may help improve patient treatment adherence and reduce the time and economic burden associated with frequent hospital visits. The Product has the potential to provide a new treatment option for patients with moderate-to-severe disease who respond poorly to conventional therapies, thereby reducing the individual and socio-economic burden associated with the disease.
On 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiary for MG-K10. In accordance with the Agreement and supplementary agreements, the Group has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon Holdings Limited has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference
- Cheng L, Chen J, Fu Q, et al. Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2018;10:300‑353.
- Zheng, Ming et al. “Clinical characteristics of allergic rhinitis patients in 13 metropolitan cities of China.” Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.14561
- White, P et al. “Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x
- Rosenblut, A et al. “Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.” Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x
- Bernstein, Jonathan A et al. “Allergic Rhinitis: A Review.” JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
From a Calling to International Recognition: ENKU Brings Japanese Calligraphy to Global Audiences
Japan, 19th Jun 2026 — Self-taught Japanese calligraphy artist ENKU is developing a contemporary body of work that combines traditional calligraphy, performance, installation art, and cultural storytelling.
Beginning his calligraphy journey in 2024 without formal training, ENKU draws inspiration from language, Japanese cultural traditions, history, and the relationship between written characters and human experience.
Through exhibitions, live performances, and collaborative projects, ENKU explores how calligraphy can be experienced not only as writing, but also as visual art, movement, sound, light, and reflection.
Latest Publicly Released Work

Exhibited in Shibuya, Tokyo, in November 2025, ENKU’s latest publicly presented work explores themes of meaning, purpose, reflection, focus, direction, and character through a composition inspired by traditional Japanese and Buddhist visual concepts. The work is structured around two symbolic worlds: one connected to spirit, wisdom, and clarity, and the other connected to life, light, and origin.
The composition brings together four interconnected concepts related to purpose, focus, direction, and character. Created using gold and silver foil, the appearance of the work changes depending on the viewer’s position and angle. ENKU created the piece with the intention of encouraging reflection, calm, and contemplation.
Koto and Calligraphy Collaboration Performance

In June 2025, ENKU presented a collaborative performance combining Japanese koto and live calligraphy. For the performance, he created a custom gold folding screen and incorporated two central themes: the miracle of life and the flow of time.
Using glow-in-the-dark materials, ENKU transformed the performance space into an immersive visual experience, expressing these ideas through lines and points of light emerging from darkness. The work invited audiences to experience changing perspectives through the folding screen structure, light, and movement.
The Story Behind the Artist
ENKU traces the beginning of his calligraphy journey to a deeply personal experience in late 2023, which inspired him to begin studying calligraphy independently in March 2024 despite having no formal training or prior experience beyond elementary school handwriting classes.
Originally drawn to language, Japanese culture, tradition, and history, ENKU’s work explores the origins and meanings of words, the beauty of written forms, and the cultural idea that words can carry influence beyond their literal definitions.
From First Exhibition Challenge to Ongoing Practice
Shortly after beginning calligraphy, ENKU decided to pursue international opportunities and applied for a New York exhibition after discovering an open call through social media. Once accepted, he faced the challenge of creating an exhibition-ready artwork despite never having made one before.
As the deadline approached, he struggled to create a work he felt satisfied with. A single phrase, translated as “Divine Wind,” came to mind, and the piece inspired by that phrase became his first exhibited work. ENKU describes this as his first major wall as an artist.
Why Calligraphy Matters in the Age of AI
ENKU believes contemporary calligraphy offers a physical, time-intensive, and human experience in an increasingly digital age. He sees the act of creating and encountering calligraphy as something that can refine people’s sensibilities and give viewers a direct experience of being alive.
At a time when AI is becoming increasingly present, ENKU’s work emphasizes hand-made expression, material presence, physical effort, and the emotional impact of written form.
Future Vision
Through calligraphy, ENKU aims to become an artist active not only in Japan but around the world. One of his long-term goals is to create a work valued at 100 million yen.
Japanese Taiko Drums, Koto, and Calligraphy Collaboration Performance

In November 2024, ENKU presented an early collaborative performance combining Japanese taiko drums, koto, and calligraphy. The performance explored the relationship between sound, language, meaning, and written expression through layered calligraphic forms.
This performance marked one of ENKU’s first attempts to expand calligraphy beyond the page and into a live, multi-sensory format.
About ENKU
ENKU is a self-taught Japanese calligraphy artist based in Tokyo. Beginning his calligraphy practice in 2024, he combines traditional Japanese calligraphy with contemporary performance, installation, light-based expression, and themes rooted in language, culture, history, and human experience.
Media Contact:
ENKU | Contemporary Calligraphy Artist
Email: enku.u.sky@gmail.com
Phone: +81 80 4189 3903
Instagram: https://www.instagram.com/enku.u_do01
LinkedIn: https://www.linkedin.com/in/enku11011
Media Contact
Organization: Contemporary calligraphy artist ENKU
Contact Person: ENKU
Website: https://www.linkedin.com/in/enku11011
Email: Send Email
Country:Japan
Release id:46259
The post From a Calling to International Recognition: ENKU Brings Japanese Calligraphy to Global Audiences appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
First Hyperliquid Holders Secure Assets Against the Quantum Threat as qVAULT Launches
qLABS launches qVAULT, secured with Falcon post-quantum cryptography, bringing quantum-resistant protection to institutional and DeFi digital asset holders.
Panama, 19th Jun 2026 – qLABS, a quantum-native Web3 foundation, today launched qVAULT, the first quantum-safe vault for digital assets for everyone. qVAULT is the first live product to let Hyperliquid holders keep HYPE, Hyperliquid’s native digital asset, in post-quantum self-custody, and the launch puts post-quantum protection, long confined to research papers and conference slides, into a product holders run themselves. The first HYPE on HyperEVM has already moved into qVAULT post-quantum vaults during early access.

qVAULT is a post-quantum, self-custody smart-contract vault for crypto that lets holders move assets out of elliptic-curve-only control and into vaults that sign with Falcon (FN-DSA), the signature scheme the U.S. National Institute of Standards and Technology (NIST) selected for standardization.
The quantum threat is concrete and present. The major public chains, including Bitcoin, Ethereum, and Hyperliquid through HyperEVM, secure funds with elliptic-curve signatures. HyperEVM authenticates with ECDSA over the secp256k1 curve, the same scheme Ethereum uses. A sufficiently capable quantum computer will break that cryptography and expose any address whose public key has appeared on chain. Because a public key revealed on chain today can be harvested and broken once that hardware exists, “harvest now, decrypt later” makes this a liability holders carry today, not a problem for a later decade.
qVAULT quantum-safe smart contract vault signs with Falcon (FN-DSA), the scheme NIST selected for standardization and currently in public review as FIPS 206. Since qVAULT is a non-custodial solution, qLABS never holds keys or seed phrases. The path into the vault has three steps: connect a self-custody account such as MetaMask, create a Falcon-secured vault, and bring assets across, out of ECDSA-only control and under a post-quantum signature.
qLABS is not making the case alone. A growing group of institutional and DeFi participants is working with the foundation on what post-quantum security means for their corner of the market. Two of them are public companies: HYLQ Strategy Corp (CSE: HYLQ), the first corporate treasury to hold HYPE, is evaluating quantum-safe custody for its position, and DigitalX (ASX: DCC), an institutional digital asset manager, recently took part in a quantum-preparedness workshop run by qLABS and 01 Quantum. On the DeFi side, the bonding protocol ApeBond is assessing post-quantum protection for its markets.
qVAULT’s design and threat model are public in a published litepaper, and its code has passed an independent security audit by Fairyproof. The cryptography itself is overseen by people who help set the standard: qLABS’ advisory board includes Dr. Edoardo Persichetti, co-author of HQC, an algorithm NIST selected for post-quantum standardization, and Aaron Moore, former CTO of QuSecure with a background at the NSA and DARPA.
Hyperliquid has become the center of gravity for on-chain trading: more than 3.5 trillion USD in cumulative volume, over 9 billion USD in open interest, and roughly 70 percent of open interest across all on-chain perpetuals exchanges, more than every competitor combined. Yet while Ethereum, Solana, and BNB Chain have all published quantum-resistance roadmaps, research, or live test results, Hyperliquid has not yet published a comparable plan. Until it does, protection in its ecosystem sits exactly where qVAULT puts it: in the hands of the holder. qONE, the qLABS native token powering qVAULT, has traded on Hyperliquid since February 2026.
“For years, post-quantum security lived in standards drafts and conference talks, with nowhere to put real money,” said Andrew Cheung, CTO of qLABS and President and CEO of 01 Quantum Inc. (TSXV: ONE; OTCQB: OONEF), a strategic partner of qLABS. “qVAULT closes that gap: a place holders move real assets onto Falcon signatures today, keep their own keys, and do it inside a live, audited smart-contract environment. That combination turns harvest-now-decrypt-later from a warning into something you can act on before the Q-Day arrives.”
“Hyperliquid is the best thing to happen to finance in years, real markets, real size, fully on-chain,” said Antanas Guoga (Tony G), President of qLABS. “The institutions and protocols that move first on post-quantum security are the ones prepared when the threat stops being theoretical. Protecting the best of on-chain finance is exactly where that starts.”
About qVAULT
qVAULT is a post-quantum, self-custody smart-contract vault for crypto. It signs with Falcon (FN-DSA), the signature scheme NIST selected for standardization and currently in public review as FIPS 206, letting holders move assets out of ECDSA-only control while retaining full custody. qLABS never holds keys or seed phrases.
Learn more: qvault.xyz
About qLABS
qLABS is a quantum-native Web3 foundation building post-quantum security for digital assets, with qVAULT as its flagship product and qONE as its native token. Its advisory board includes Dr. Edoardo Persichetti, co-author of the NIST-selected HQC algorithm, and Aaron Moore, former CTO of QuSecure. 01 Quantum Inc. (TSXV: ONE; OTCQB: OONEF) is a strategic technological partner of qLABS.
For more details contact: gintautas@qlabs.tech
Media Contact
Organization: qLABS
Contact Person: Ada Jonuse
Website: https://qlabs.tech/
Email: Send Email
Country:Panama
Release id:46266
The post First Hyperliquid Holders Secure Assets Against the Quantum Threat as qVAULT Launches appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Tradesman Nutrition Reviews Highlight Strong Demand for Supplements Built for Blue Collar Workers Across the United States
San Francisco, CA, Jun 19, 2026, ZEX PR WIRE — Tradesman Nutrition is gaining growing attention across the supplement industry. Thousands of American blue-collar workers are turning to the brand for practical nutrition solutions designed around demanding physical jobs. The company is receiving a steady stream of positive customer feedback. Many reviews highlight improvements in energy, weight management, recovery, and overall daily performance.

Unlike traditional supplement brands that mainly target athletes or gym-focused consumers, Tradesman Nutrition takes a different approach. It focuses on the needs of everyday working men. The company designs its products for people working long hours in construction, electrical work, plumbing, carpentry, mechanical trades, and other physically demanding industries. These jobs require sustained energy and strong recovery.
The company explains its mission in simple terms. It aims to help working men improve fitness and energy levels. It also focuses on helping them perform at a higher standard without forcing major lifestyle changes. Customers are not asked to completely change their routines. Instead, the products are designed to fit into existing work schedules and habits.
This approach is resonating strongly with customers. Thousands of reviews across the product range reflect this response. Many users describe clear and practical benefits that relate directly to their daily work lives.
One customer, Merv A, a 60-year-old painter, shared a simple but powerful transformation. He said, “Haven’t worn my old work shirt in years, fits again now.”
Weight management and physical improvement appear often in customer feedback. Another reviewer, Shane S, a 41-year-old carpenter, reported noticeable changes while using the company’s Shred product. He said, “Been on the Shred for a few weeks and love it. Feels like it’s shredding fat while keeping me moving all day.”
Affordability and practicality are also important drivers of customer satisfaction. James C, a 21-year-old apprentice electrician, explained the financial benefit compared to his daily spending habits. He said, “As an apprentice, I was sick of paying 7 dollars a day at the servo, so happy I found something way cheaper and it works way better.”
These testimonials reflect a broader pattern across the customer base. Many tradesmen are looking for simple ways to improve health without adding complexity to their already demanding schedules. Reviewers often mention that the products fit easily into their daily routines. This includes use on job sites, during travel, and in early morning starts.
A major theme in Tradesman Nutrition Reviews is sustained energy throughout long workdays. Customers frequently report improved endurance. They also describe reduced fatigue and better focus during long shifts. For workers who start early and finish late, steady energy is important for both productivity and safety.
Weight management is another commonly reported benefit. Many customers who use Shred and related products report visible changes in body composition. They report these results while continuing physically intense labor. Unlike structured fitness programs that require gym time and strict dieting, users say the products integrate naturally into their work routines.
Recovery and rest also appear often in customer feedback. Many tradesmen report improved sleep quality and faster recovery after demanding workdays. Given the physical strain of blue-collar work, this benefit has become a key factor in customer satisfaction.
The company reports serving more than 100,000 American blue-collar workers. It also maintains a 4.9-star average rating among its customers. Thousands of reviews across multiple products continue to reinforce its market position. These products include Energy Drink, Sleep formula, Shred, T Fuel, and Creatine. The feedback supports its identity as a brand created for working men rather than general fitness consumers.
Another consistent theme in reviews is accessibility. Many customers say they had never considered supplements before discovering Tradesman Nutrition. The brand’s focused messaging has introduced nutrition support to a new audience. These are men who view nutrition as a practical tool for work performance rather than a fitness luxury.
As the company continues to expand across the United States, customer testimonials suggest strong alignment between product design and real-world needs. The focus on simplicity, affordability, and work-driven performance has helped it stand out in a crowded supplement market.
With thousands of positive reviews and growing recognition among American tradesmen, Tradesman Nutrition shows that supplements designed for physically demanding jobs can meet a long-overlooked need in the wellness industry. For many customers, the message is clear. When products are built for the realities of hard work, the results become visible in everyday life. To learn more, visit: https://tradesmannutrition.com/ .
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release3 days ago
FARO Board Bags Expands Premium Surf Gear Line with Durable Surfboard Protection and Sustainable Travel Solutions in the USA
-
Press Release3 days ago
MAMBASNAKE Launches “World Football Season” Mid-Year Sale: Celebrate the Spirit of the World Cup with Elite Gaming Gear
-
Press Release6 days ago
MarketAnywhere Sets the National Standard for Best Flyer Distribution and Door-to-Door Marketing in the United States
-
Press Release1 week ago
GLP-1 Patients Regain Most of Their Lost Weight Within 2 Years . A Tampa Telehealth Provider Is Partnering With a Digital Health Platform to Change That.
-
Press Release6 days ago
isCalculator: The Evolution Of No-Code; Ai Platform Instantly Generates Mathematical Mini-Applications
-
Press Release6 days ago
The Surgeon Everyone Sees on the Way to the Hamptons: Dr. David Pincus of Pincus Plastic Surgery
-
Press Release6 days ago
The Point Elevates Coastal Celebrations with Premier Waterfront Event Venue in Mission Beach, San Diego
-
Press Release1 week ago
Jerky Didn’t Need Another Flavor It Needed a Personality
